Skip to Main Content

Sandra Springer, MD

Associate Professor of Medicine (AIDS) and Associate Clinical Professor of Nursing; Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington


Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD). Her research has focused on evaluation of integration of SUD and HIV treatments. In particular, she has focused on medication treatment for opioid use disorder (OUD) (MOUD) and medication treatment for alcohol use disorders (AUD) to improve substance use relapse outcomes and HIV treatment outcomes, especially among those released from prison and jail. Dr. Springer has been continuously NIH funded for over 15 years. She has a K02 Independent Scientist Award from NIDA evaluating medication treatment for OUD (MOUD) interventions among PLH. Dr. Springer has been a buprenorphine provider since 2005, and performed the first evaluation of the use of buprenorphine to prevent relapse to opioid use and improve HIV viral suppression among PLH released from prison. She created and later validated a rapid opioid dependency screen (RODS) that quickly identifies if someone has a moderate to severe opioid use disorder (OUD) to quickly initiate MOUD. She has studied extended-release naltrexone (XR-NTX) as a PI on a 5 year NIAAA-funded R01 which used a RCT design to evaluate its effect on improving HIV viral suppression for PLH released from prison; and she was a PI on a NIDA-funded R01 within the Seek Test Treat and Retain (STTR) Criminal Justice System (CJS) consortium to evaluate the use of XR-NTX to improve HIV VS among PLH with OUD released from prison/jail. Dr. Springer was a working group member of the NIDA STTR consortium that harmonized outcomes across 23 NIDA-funded STTR studies involving PLH and those who are at risk for HIV. Additionally, she was co-I on 2 NIDA R01s (1) using Buprenorphine to improve HIV treatment outcomes among CJS-involved PLH with OUD in Washington, D.C.; and (2) implementing XR-NTX among PLH with OUD in Ukraine. She is currently co-PI on a 5-year R01 from NIDA evaluating the impact of HIV infection on immunologic, transcriptomic, and metabolomic signatures among PLH compared to those without HIV infection who are beginning MAT for OUD. She is a co-PI with Drs. Ho and Kluger at Yale for a NIDA funded R33/R61 that is specifically evaluating the impact of all forms of MAT on HIV persistence; and she is a co-I on a HEALing NIDA funded grant to combat Opioid addiction in NY State. She is also the contact PI of a new U01 from NCATS that will integrate ID and injectable buprenorphine in hospitalized patients. She also is a co-PI on a new Justice involved HEALing grant at the NYU site with Dr. Josh Lee from NIDA evaluating OUD medication treatment for criminal justice involved persons with OUD and co-PI with Dr. Ismene Petrakis for a VA COOP grant among 900 Veterans with OUD comparing injectable and sublingual buprenorphine. She is a member of IDSA and HIVMA’s expert panel to integrate ID and OUD, a NASEM committee member evaluating the integration of ID and OUD treatment and prevention in community settings nationally, and a member of the ASAM committee that provided updated recommendations for use of MOUD in 2020.

Education & Training

  • Fellow
    Yale School of Medicine (2004)
  • Resident
    Yale School of Medicine (2001)
  • MD
    University of Massachusetts Medical School, Medicine (1998)
  • BA
    Harvard University (1990)


  • HIV/AIDS and Addiction
    Kiev, Ukraine (2012-2017)
    Technical Assistance and Research, implementation protocol for extended-release naltrexone in Ukraine

Honors & Recognition

AwardAwarding OrganizationDate
Invited Chair and Discussion of "Integrative Research on Injectable Extended-Release Naltrexone"Research Society on Alcoholism2012
Independent Scientist K-02 AwardNational Institute of Drug Abuse2011
Invited Reviewer of R01 GrantsNational Institute of Drug Abuse (NIDA)2011
Award for Outstanding Provider in the CommunityVNA- South Central Partnership2007
Recipient of the 2006 B. Jaye Anno Award of Excellence in Communication 2006
Mentored Career Development K-23 AwardNational Institute of Drug Abuse2005
Bristol-Myers Squibb HIV Virology Fellowship AwardBristo-Myers Squibb2002
Academic Excellence Award for Women in Field of MedicineUniversity of Massachusetts Medical School1998

Departments & Organizations